Insmed (INSM) Cash from Financing Activities (2010 - 2026)
Insmed (INSM) posted quarterly Cash from Financing Activities of $29.5 million for Q1 2026, up 1.78% year-over-year from $29.0 million in Q1 2025, and down 12.83% quarter-over-quarter from $33.9 million in Q4 2025.
Insmed (INSM) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Insmed's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $29.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 1.78% year-over-year to $29.5 million; the TTM figure through Mar 2026 stood at $954.6 million (down 30.17% YoY), while the FY2025 annual figure was $954.1 million, down 28.85% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $29.5 million, down from $33.9 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $857.8 million in Q2 2025, with the low at -$399000.0 in Q1 2023.
- The 5-year median for Cash from Financing Activities is $33.9 million (2025), against an average of $193.3 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities plunged 106.18% in 2023, then jumped 31701.44% in 2024.
- Insmed's Cash from Financing Activities stood at $743.4 million in 2022, then plunged by 83.42% to $123.3 million in 2023, then rose by 29.24% to $159.3 million in 2024, then slumped by 78.75% to $33.9 million in 2025, then decreased by 12.83% to $29.5 million in 2026.
- Business Quant data shows INSM's Cash from Financing Activities at $29.5 million in Q1 2026, $33.9 million in Q4 2025, and $33.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -181.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.18 Mn |
| Jun 30, 2026 | 27.18 Mn |
| Mar 31, 2026 | 29.51 Mn |
| Mar 31, 2026 | 29.51 Mn |
| Dec 31, 2025 | 33.86 Mn |
| Dec 31, 2025 | 33.86 Mn |
| Sep 30, 2025 | 33.41 Mn |
| Sep 30, 2025 | 33.41 Mn |
| Jun 30, 2025 | 857.81 Mn |
| Jun 30, 2025 | 857.81 Mn |
| Mar 31, 2025 | 29.00 Mn |
| Mar 31, 2025 | 29.00 Mn |
| Dec 31, 2024 | 159.31 Mn |
| Dec 31, 2024 | 159.31 Mn |
| Sep 30, 2024 | 397.20 Mn |
| Sep 30, 2024 | 397.20 Mn |
| Jun 30, 2024 | 781.49 Mn |
| Jun 30, 2024 | 781.49 Mn |
| Mar 31, 2024 | 3.02 Mn |
| Mar 31, 2024 | 3.02 Mn |